News Laboratorios Farmaceuticos Rovi, S.A. OTC Markets

Stocks

LABFF

ES0157261019

Pharmaceuticals

Market Closed - OTC Markets 15:45:10 20/10/2023 BST			5-day change	1st Jan Change
52.00 ^USD	-3.93%		-22.58%	-21.05%

07-23	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
07-23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

07-23	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
07-23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-23	Laboratorios Farmaceuticos Rovi, S.A. Maintains Earnings Guidance for 2026	CI
07-23	Laboratorios Farmaceuticos Rovi S A : First half 2026 results press release	PU
07-08	Laboratorios Farmaceuticos Rovi S A : ROVI and the Regional Government of Castilla-La Mancha promote a framework of collaboration to modernise healthcare services through technological innovation	PU
05-09	Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026
05-06	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Laboratorios Farmaceuticos Rovi, S.A. Updates Earnings Guidance for the Full Year 2026	CI
05-06	Rovi Q1 net profit at 9.4 mln euros	RE
05-06	Rovi expects risperidone to reach potential sales of 100-200 mln euros globally over next few years	RE
05-06	Laboratorios Farmaceuticos Rovi S A : First three months of 2026 results press release	PU
04-01	Rovi closes deal to buy pharmaceutical manufacturing facility in US	RE
02-25	Laboratorios Farmaceuticos Rovi, S.A., 2025 Earnings Call, Feb 25, 2026
02-25	Pharmaceutical Company Rovi Increases Net Profit Thanks to Okedi and Heparin Sales	RE
02-25	Drugmaker Rovi's net profit rises on higher Okedi, heparin sales	RE
02-25	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Laboratorios Farmaceuticos Rovi, S.A. Provides Earnings Guidance for the Fiscal Year 2026	CI
02-25	ROVI Proposes Dividend Distribution for the Year 2025	CI
02-25	Laboratorios Farmaceuticos Rovi S A : 2025 results press release	PU
02-25	Rovi to propose dividend of 0.9594 eur/shr	RE
02-25	Rovi FY Ebitda 216.2 mln euros	RE
02-25	Rovi FY net profit at 140.4 mln euros	RE
11-18	Rovi and Roche sign final agreement for manufacture of new medicine	RE
11-18	Laboratorios Farmaceuticos Rovi S A : ROVI releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development	PU
11-06	Rovi sees 2026 operating revenue to increase by up to low double-digit percentage vs 2025	RE